PMID- 29549977
OWN - NLM
STAT- MEDLINE
DCOM- 20191028
LR  - 20231108
IS  - 1872-9142 (Electronic)
IS  - 0161-5890 (Print)
IS  - 0161-5890 (Linking)
VI  - 110
DP  - 2019 Jun
TI  - Molecular regulation of dendritic cell development and function in homeostasis, 
      inflammation, and cancer.
PG  - 24-39
LID - S0161-5890(18)30021-X [pii]
LID - 10.1016/j.molimm.2018.01.014 [doi]
AB  - Dendritic cells (DCs) are the principal antigen-presenting cells of the immune 
      system and play key roles in controlling immune tolerance and activation. As 
      such, DCs are chief mediators of tumor immunity. DCs can regulate tolerogenic 
      immune responses that facilitate unchecked tumor growth. Importantly, however, 
      DCs also mediate immune-stimulatory activity that restrains tumor progression. 
      For instance, emerging evidence indicates the cDC1 subset has important functions 
      in delivering tumor antigens to lymph nodes and inducing antigen-specific 
      lymphocyte responses to tumors. Moreover, DCs control specific therapeutic 
      responses in cancer including those resulting from immune checkpoint blockade. DC 
      generation and function is influenced profoundly by cytokines, as well as their 
      intracellular signaling proteins including STAT transcription factors. 
      Regardless, our understanding of DC regulation in the cytokine-rich tumor 
      microenvironment is still developing and must be better defined to advance cancer 
      treatment. Here, we review literature focused on the molecular control of DCs, 
      with a particular emphasis on cytokine- and STAT-mediated DC regulation. In 
      addition, we highlight recent studies that delineate the importance of DCs in 
      anti-tumor immunity and immune therapy, with the overall goal of improving 
      knowledge of tumor-associated factors and intrinsic DC signaling cascades that 
      influence DC function in cancer.
CI  - Copyright (c) 2018 Elsevier Ltd. All rights reserved.
FAU - Chrisikos, Taylor T
AU  - Chrisikos TT
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA; The University of Texas Graduate School of Biomedical 
      Sciences, Houston, TX, 77030, USA.
FAU - Zhou, Yifan
AU  - Zhou Y
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA.
FAU - Slone, Natalie
AU  - Slone N
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA; Division of Pediatrics, The University of Texas MD 
      Anderson Cancer Center, Houston, TX, 77030, USA.
FAU - Babcock, Rachel
AU  - Babcock R
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA; The University of Texas Graduate School of Biomedical 
      Sciences, Houston, TX, 77030, USA.
FAU - Watowich, Stephanie S
AU  - Watowich SS
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA; The University of Texas Graduate School of Biomedical 
      Sciences, Houston, TX, 77030, USA. Electronic address: swatowic@mdanderson.org.
FAU - Li, Haiyan S
AU  - Li HS
AD  - Department of Immunology, The University of Texas MD Anderson Cancer Center, 
      Houston, TX, 77030, USA. Electronic address: haiyanli@mdanderson.org.
LA  - eng
GR  - R01 AI109294/AI/NIAID NIH HHS/United States
GR  - R56 AI109294/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180315
PL  - England
TA  - Mol Immunol
JT  - Molecular immunology
JID - 7905289
SB  - IM
MH  - Animals
MH  - Cell Differentiation/*genetics
MH  - Dendritic Cells/*physiology
MH  - *Homeostasis/genetics/immunology
MH  - Humans
MH  - *Inflammation/genetics/immunology/pathology
MH  - *Neoplasms/genetics/immunology/pathology
PMC - PMC6139080
MID - NIHMS951473
OTO - NOTNLM
OT  - Antigen presentation
OT  - Cytokine
OT  - Dendritic cell
OT  - Molecular regulation
OT  - STAT
OT  - Tumor
COIS- Declaration of Interest The authors declare no competing financial interests. 
      None of the authors affiliated with this manuscript have any commercial or 
      associations that might pose a conflict interest.
EDAT- 2018/03/20 06:00
MHDA- 2019/10/29 06:00
PMCR- 2020/06/01
CRDT- 2018/03/19 06:00
PHST- 2017/07/22 00:00 [received]
PHST- 2018/01/04 00:00 [revised]
PHST- 2018/01/25 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2019/10/29 06:00 [medline]
PHST- 2018/03/19 06:00 [entrez]
PHST- 2020/06/01 00:00 [pmc-release]
AID - S0161-5890(18)30021-X [pii]
AID - 10.1016/j.molimm.2018.01.014 [doi]
PST - ppublish
SO  - Mol Immunol. 2019 Jun;110:24-39. doi: 10.1016/j.molimm.2018.01.014. Epub 2018 Mar 
      15.